0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-23E17862
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Bioabsorbable Sirolimus eluting Coronary Stent System Market Research Report 2024
BUY CHAPTERS

Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-23E17862
Report
October 2025
Pages:149
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Bioabsorbable Sirolimus-eluting Coronary Stent System Market

The global Bioabsorbable Sirolimus-eluting Coronary Stent System market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
A bioabsorbable sirolimus-eluting coronary stent system is an advanced medical device used to treat narrowed or blocked coronary arteries. This system consists of a stent made from bioabsorbable materials and coated with sirolimus, a drug that helps to inhibit restenosis. Once implanted into the coronary artery, the stent provides mechanical support to keep the vessel open, while the sirolimus coating gradually releases the drug to inhibit endothelial cell proliferation, reducing the risk of restenosis. Over time, the bioabsorbable stent is gradually absorbed by the body, reducing the complications associated with long-term implantation and allowing the vessel to return to its natural function.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Bioabsorbable Sirolimus-eluting Coronary Stent System leading manufacturers including Q3 Medical, Shandong Huaan Biotechnology, MicroPort, Lepu, Bioheart, Micell Technologies Ireland, etc., dominate supply; the top five capture approximately % of global revenue, with Q3 Medical leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Bioabsorbable Sirolimus-eluting Coronary Stent System market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Bioabsorbable Sirolimus-eluting Coronary Stent System Market Report

Report Metric Details
Report Name Bioabsorbable Sirolimus-eluting Coronary Stent System Market
Segment by Type
  • Polylactic Acid (PLA)
  • Polyglycolic Acid (PGA)
Segment by Application
  • Hospital
  • Clinic
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Q3 Medical, Shandong Huaan Biotechnology, MicroPort, Lepu, Bioheart, Micell Technologies Ireland
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Bioabsorbable Sirolimus-eluting Coronary Stent System study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Bioabsorbable Sirolimus-eluting Coronary Stent System Market report?

Ans: The main players in the Bioabsorbable Sirolimus-eluting Coronary Stent System Market are Q3 Medical, Shandong Huaan Biotechnology, MicroPort, Lepu, Bioheart, Micell Technologies Ireland

What are the Application segmentation covered in the Bioabsorbable Sirolimus-eluting Coronary Stent System Market report?

Ans: The Applications covered in the Bioabsorbable Sirolimus-eluting Coronary Stent System Market report are Hospital, Clinic

What are the Type segmentation covered in the Bioabsorbable Sirolimus-eluting Coronary Stent System Market report?

Ans: The Types covered in the Bioabsorbable Sirolimus-eluting Coronary Stent System Market report are Polylactic Acid (PLA), Polyglycolic Acid (PGA)

1 Study Coverage
1.1 Introduction to Bioabsorbable Sirolimus-eluting Coronary Stent System: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Polylactic Acid (PLA)
1.2.3 Polyglycolic Acid (PGA)
1.3 Market Segmentation by Application
1.3.1 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Estimates and Forecasts 2020-2031
2.2 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Estimates and Forecasts 2020-2031
2.4 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Polylactic Acid (PLA) Market Size by Manufacturers
3.5.2 Polyglycolic Acid (PGA) Market Size by Manufacturers
3.6 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Type (2020-2031)
6.4 North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Type (2020-2031)
7.4 Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Type (2020-2031)
9.4 Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Q3 Medical
11.1.1 Q3 Medical Corporation Information
11.1.2 Q3 Medical Business Overview
11.1.3 Q3 Medical Bioabsorbable Sirolimus-eluting Coronary Stent System Product Models, Descriptions and Specifications
11.1.4 Q3 Medical Bioabsorbable Sirolimus-eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Q3 Medical Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Product in 2024
11.1.6 Q3 Medical Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application in 2024
11.1.7 Q3 Medical Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Geographic Area in 2024
11.1.8 Q3 Medical Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
11.1.9 Q3 Medical Recent Developments
11.2 Shandong Huaan Biotechnology
11.2.1 Shandong Huaan Biotechnology Corporation Information
11.2.2 Shandong Huaan Biotechnology Business Overview
11.2.3 Shandong Huaan Biotechnology Bioabsorbable Sirolimus-eluting Coronary Stent System Product Models, Descriptions and Specifications
11.2.4 Shandong Huaan Biotechnology Bioabsorbable Sirolimus-eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Shandong Huaan Biotechnology Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Product in 2024
11.2.6 Shandong Huaan Biotechnology Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application in 2024
11.2.7 Shandong Huaan Biotechnology Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Geographic Area in 2024
11.2.8 Shandong Huaan Biotechnology Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
11.2.9 Shandong Huaan Biotechnology Recent Developments
11.3 MicroPort
11.3.1 MicroPort Corporation Information
11.3.2 MicroPort Business Overview
11.3.3 MicroPort Bioabsorbable Sirolimus-eluting Coronary Stent System Product Models, Descriptions and Specifications
11.3.4 MicroPort Bioabsorbable Sirolimus-eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 MicroPort Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Product in 2024
11.3.6 MicroPort Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application in 2024
11.3.7 MicroPort Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Geographic Area in 2024
11.3.8 MicroPort Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
11.3.9 MicroPort Recent Developments
11.4 Lepu
11.4.1 Lepu Corporation Information
11.4.2 Lepu Business Overview
11.4.3 Lepu Bioabsorbable Sirolimus-eluting Coronary Stent System Product Models, Descriptions and Specifications
11.4.4 Lepu Bioabsorbable Sirolimus-eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Lepu Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Product in 2024
11.4.6 Lepu Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application in 2024
11.4.7 Lepu Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Geographic Area in 2024
11.4.8 Lepu Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
11.4.9 Lepu Recent Developments
11.5 Bioheart
11.5.1 Bioheart Corporation Information
11.5.2 Bioheart Business Overview
11.5.3 Bioheart Bioabsorbable Sirolimus-eluting Coronary Stent System Product Models, Descriptions and Specifications
11.5.4 Bioheart Bioabsorbable Sirolimus-eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Bioheart Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Product in 2024
11.5.6 Bioheart Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application in 2024
11.5.7 Bioheart Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Geographic Area in 2024
11.5.8 Bioheart Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
11.5.9 Bioheart Recent Developments
11.6 Micell Technologies Ireland
11.6.1 Micell Technologies Ireland Corporation Information
11.6.2 Micell Technologies Ireland Business Overview
11.6.3 Micell Technologies Ireland Bioabsorbable Sirolimus-eluting Coronary Stent System Product Models, Descriptions and Specifications
11.6.4 Micell Technologies Ireland Bioabsorbable Sirolimus-eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Micell Technologies Ireland Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Bioabsorbable Sirolimus-eluting Coronary Stent System Industry Chain
12.2 Bioabsorbable Sirolimus-eluting Coronary Stent System Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Bioabsorbable Sirolimus-eluting Coronary Stent System Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Bioabsorbable Sirolimus-eluting Coronary Stent System Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Bioabsorbable Sirolimus-eluting Coronary Stent System Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Region (2020-2025) & (K Units)
 Table 8. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Share by Manufacturers (2020-2025)
 Table 12. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Bioabsorbable Sirolimus-eluting Coronary Stent System by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bioabsorbable Sirolimus-eluting Coronary Stent System as of 2024)
 Table 16. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Bioabsorbable Sirolimus-eluting Coronary Stent System Manufacturing Base and Headquarters
 Table 19. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Type (2020-2025) & (K Units)
 Table 23. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Type (2026-2031) & (K Units)
 Table 24. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Bioabsorbable Sirolimus-eluting Coronary Stent System ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application (2020-2025) & (K Units)
 Table 29. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales by Application (2026-2031) & (K Units)
 Table 30. Bioabsorbable Sirolimus-eluting Coronary Stent System High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Bioabsorbable Sirolimus-eluting Coronary Stent System ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Growth Accelerators and Market Barriers
 Table 37. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Growth Accelerators and Market Barriers
 Table 40. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Investment Opportunities and Key Challenges
 Table 47. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Q3 Medical Corporation Information
 Table 51. Q3 Medical Description and Major Businesses
 Table 52. Q3 Medical Product Models, Descriptions and Specifications
 Table 53. Q3 Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Q3 Medical Sales Value Proportion by Product in 2024
 Table 55. Q3 Medical Sales Value Proportion by Application in 2024
 Table 56. Q3 Medical Sales Value Proportion by Geographic Area in 2024
 Table 57. Q3 Medical Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
 Table 58. Q3 Medical Recent Developments
 Table 59. Shandong Huaan Biotechnology Corporation Information
 Table 60. Shandong Huaan Biotechnology Description and Major Businesses
 Table 61. Shandong Huaan Biotechnology Product Models, Descriptions and Specifications
 Table 62. Shandong Huaan Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Shandong Huaan Biotechnology Sales Value Proportion by Product in 2024
 Table 64. Shandong Huaan Biotechnology Sales Value Proportion by Application in 2024
 Table 65. Shandong Huaan Biotechnology Sales Value Proportion by Geographic Area in 2024
 Table 66. Shandong Huaan Biotechnology Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
 Table 67. Shandong Huaan Biotechnology Recent Developments
 Table 68. MicroPort Corporation Information
 Table 69. MicroPort Description and Major Businesses
 Table 70. MicroPort Product Models, Descriptions and Specifications
 Table 71. MicroPort Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. MicroPort Sales Value Proportion by Product in 2024
 Table 73. MicroPort Sales Value Proportion by Application in 2024
 Table 74. MicroPort Sales Value Proportion by Geographic Area in 2024
 Table 75. MicroPort Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
 Table 76. MicroPort Recent Developments
 Table 77. Lepu Corporation Information
 Table 78. Lepu Description and Major Businesses
 Table 79. Lepu Product Models, Descriptions and Specifications
 Table 80. Lepu Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Lepu Sales Value Proportion by Product in 2024
 Table 82. Lepu Sales Value Proportion by Application in 2024
 Table 83. Lepu Sales Value Proportion by Geographic Area in 2024
 Table 84. Lepu Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
 Table 85. Lepu Recent Developments
 Table 86. Bioheart Corporation Information
 Table 87. Bioheart Description and Major Businesses
 Table 88. Bioheart Product Models, Descriptions and Specifications
 Table 89. Bioheart Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Bioheart Sales Value Proportion by Product in 2024
 Table 91. Bioheart Sales Value Proportion by Application in 2024
 Table 92. Bioheart Sales Value Proportion by Geographic Area in 2024
 Table 93. Bioheart Bioabsorbable Sirolimus-eluting Coronary Stent System SWOT Analysis
 Table 94. Bioheart Recent Developments
 Table 95. Micell Technologies Ireland Corporation Information
 Table 96. Micell Technologies Ireland Description and Major Businesses
 Table 97. Micell Technologies Ireland Product Models, Descriptions and Specifications
 Table 98. Micell Technologies Ireland Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Micell Technologies Ireland Recent Developments
 Table 100. Key Raw Materials Distribution
 Table 101. Raw Materials Key Suppliers
 Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 103. Milestones in Production Technology Evolution
 Table 104. Distributors List
 Table 105. Market Trends and Market Evolution
 Table 106. Market Drivers and Opportunities
 Table 107. Market Challenges, Risks, and Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources


List of Figures
 Figure 1. Bioabsorbable Sirolimus-eluting Coronary Stent System Product Picture
 Figure 2. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Polylactic Acid (PLA) Product Picture
 Figure 4. Polyglycolic Acid (PGA) Product Picture
 Figure 5. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospital
 Figure 7. Clinic
 Figure 8. Bioabsorbable Sirolimus-eluting Coronary Stent System Report Years Considered
 Figure 9. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Market Share by Region (2020-2031)
 Figure 13. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales (2020-2031) & (K Units)
 Figure 14. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 15. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Market Share by Region (2020-2031)
 Figure 16. Top 5 and Top 10 Manufacturers Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume Market Share in 2024
 Figure 17. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Polylactic Acid (PLA) Revenue Market Share by Manufacturer in 2024
 Figure 20. Polyglycolic Acid (PGA) Revenue Market Share by Manufacturer in 2024
 Figure 21. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Market Share by Type (2020-2031)
 Figure 22. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Market Share by Type (2020-2031)
 Figure 23. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Market Share by Application (2020-2031)
 Figure 24. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue Market Share by Application (2020-2031)
 Figure 25. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)
 Figure 26. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Manufacturers Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) in 2024
 Figure 28. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Type (2020- 2031)
 Figure 29. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)
 Figure 31. North America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 32. US Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 33. Canada Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 34. Mexico Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 35. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)
 Figure 36. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Europe Top 5 Manufacturers Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) in 2024
 Figure 38. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Type (2020-2031)
 Figure 39. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)
 Figure 41. Europe Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Germany Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 43. France Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 44. U.K. Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 45. Italy Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 46. Russia Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 47. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)
 Figure 48. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Top 8 Manufacturers Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) in 2024
 Figure 50. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Type (2020- 2031)
 Figure 51. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 52. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)
 Figure 53. Asia-Pacific Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 54. Indonesia Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 55. Japan Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 56. South Korea Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 57. China Taiwan Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 58. India Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)
 Figure 59. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)
 Figure 60. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Central and South America Top 5 Manufacturers Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) in 2024
 Figure 62. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Type (2021-2031)
 Figure 63. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 64. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)
 Figure 65. Central and South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 66. Brazil Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)
 Figure 67. Argentina Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)
 Figure 68. Middle East, and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)
 Figure 69. Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)
 Figure 70. Middle East and Africa Top 5 Manufacturers Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) in 2024
 Figure 71. Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Type (2021-2031)
 Figure 72. South America Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 73. Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)
 Figure 74. Middle East and Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 75. GCC Countries Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)
 Figure 76. Turkey Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)
 Figure 77. Egypt Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)
 Figure 78. South Africa Bioabsorbable Sirolimus-eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)
 Figure 79. Bioabsorbable Sirolimus-eluting Coronary Stent System Industry Chain Mapping
 Figure 80. Regional Bioabsorbable Sirolimus-eluting Coronary Stent System Manufacturing Base Distribution (%)
 Figure 81. Global Bioabsorbable Sirolimus-eluting Coronary Stent System Production Market Share by Region (2020-2031)
 Figure 82. Bioabsorbable Sirolimus-eluting Coronary Stent System Production Process
 Figure 83. Regional Bioabsorbable Sirolimus-eluting Coronary Stent System Production Cost Structure
 Figure 84. Channels of Distribution (Direct Vs Distribution)
 Figure 85. Bottom-up and Top-down Approaches for This Report
 Figure 86. Data Triangulation
 Figure 87. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32P14840
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Point-of-care Troponin Testing Instrument Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22I19939
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Troponin Analyzer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-38W19812
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Anticoagulant Medications Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-39V16824
Wed Nov 12 00:00:00 UTC 2025

Add to Cart